Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease

[1]  Marcel Zeelenberg,et al.  Data analysis 2 , 2016 .

[2]  Lea T Grinberg,et al.  Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. , 2016, Cerebral cortex.

[3]  Olivier Salvado,et al.  Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease , 2014, NeuroImage: Clinical.

[4]  P. Snyder,et al.  APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease , 2014, Molecular Psychiatry.

[5]  Rebecca A Betensky,et al.  Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.

[6]  P. Snyder,et al.  Microdosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at-risk cohort of older adults , 2014, Alzheimer's & Dementia.

[7]  P. Snyder,et al.  Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease , 2013, BMC psychology.

[8]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[9]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[10]  Shauna M. Stark,et al.  A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment , 2013, Neuropsychologia.

[11]  E. Siegel,et al.  Psychometric Limitations of the Mini-Mental State Examination Among Nondemented Older Adults: An Evaluation of Neurocognitive and Magnetic Resonance Imaging Correlates , 2013, Experimental aging research.

[12]  Federico Nemmi,et al.  Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients , 2013, EJNMMI Research.

[13]  H. Heinsen,et al.  Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease , 2013, Neurobiology of Aging.

[14]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[15]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[16]  R. Gross.  Spotlight on the January 1 Issue , 2013, Neurology.

[17]  C. Rowe,et al.  Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.

[18]  James Robert Brašić,et al.  Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  B. Pollock,et al.  Drugs with anticholinergic properties: a current perspective on use and safety , 2011, Expert opinion on drug safety.

[20]  T. Arendt,et al.  The cholinergic system in aging and neuronal degeneration , 2011, Behavioural Brain Research.

[21]  Reisa A. Sperling,et al.  Face-name associative memory performance is related to amyloid burden in normal elderly , 2011, Neuropsychologia.

[22]  D. Gozal,et al.  Intermittent Hypoxia-Induced Cognitive Deficits Are Mediated by NADPH Oxidase Activity in a Murine Model of Sleep Apnea , 2011, PloS one.

[23]  M. Sabbagh,et al.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.

[24]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[25]  K. Amunts,et al.  Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. , 2010, Cerebral cortex.

[26]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[27]  P. Snyder,et al.  A method for cross-cultural adaptation of a verbal memory assessment , 2009, Behavior research methods.

[28]  P. Snyder,et al.  The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine , 2008, Human psychopharmacology.

[29]  Paul Maruff,et al.  Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor , 2005, Alzheimer's & Dementia.

[30]  S. Pimlott,et al.  Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  F. D. de Abajo,et al.  Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations , 2001, BMC clinical pharmacology.

[32]  T. Beach,et al.  The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[33]  W. Honer,et al.  Cortical Cholinergic Denervation Elicits Vascular Aβ Deposition , 2000 .

[34]  L. H. Hughes,et al.  Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer’s disease? , 1997, Acta Neuropathologica.

[35]  S. Corkin.  Acetylcholine, aging and Alzheimer's disease Implications for treatment , 1981, Trends in Neurosciences.

[36]  Paul Maruff,et al.  Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people , 2014, Comput. Hum. Behav..

[37]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[38]  J. Stockman,et al.  Longitudinal Modeling of Age-Related Memory Decline and the APOE ɛ4 Effect , 2011 .

[39]  W. Honer,et al.  Cortical cholinergic denervation elicits vascular A beta deposition. , 2000, Annals of the New York Academy of Sciences.